RECRUITING

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Description

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Conditions

Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer
Talk to us

Related Conditions:

Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer

Study Overview

On this page

Study Details

Study overview

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Condition
Renal Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

San Antonio

NEXT Oncology, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
  • * Able to take oral medication
  • * If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
  • * Adequate organ function and electrolytes
  • * Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
  • * Impaired cardiac function
  • * Major surgery within 28 days of the first dose of study drug

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Deciphera Pharmaceuticals, LLC,

Clinical Team, STUDY_DIRECTOR, Deciphera Pharmaceuticals, LLC

Study Record Dates

2029-02